ID   ACHB2_RAT               Reviewed;         500 AA.
AC   P12390; Q53YK1;
DT   01-OCT-1989, integrated into UniProtKB/Swiss-Prot.
DT   30-MAY-2000, sequence version 2.
DT   29-MAY-2024, entry version 193.
DE   RecName: Full=Neuronal acetylcholine receptor subunit beta-2;
DE   AltName: Full=Neuronal acetylcholine receptor non-alpha-1 chain;
DE            Short=N-alpha 1;
DE   Flags: Precursor;
GN   Name=Chrnb2; Synonyms=Acrb2;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=3272154; DOI=10.1016/0896-6273(88)90208-5;
RA   Deneris E.S., Connolly J.G., Boulter J., Wada E., Wada K., Swanson L.W.,
RA   Patrick J., Heinemann S.F.;
RT   "Primary structure and expression of beta 2: a novel subunit of neuronal
RT   nicotinic acetylcholine receptors.";
RL   Neuron 1:45-54(1988).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=2444984; DOI=10.1073/pnas.84.21.7763;
RA   Boulter J., Connolly J.G., Deneris E.S., Goldman D.J., Heinemann S.F.,
RA   Patrick J.;
RT   "Functional expression of two neuronal nicotinic acetylcholine receptors
RT   from cDNA clones identifies a gene family.";
RL   Proc. Natl. Acad. Sci. U.S.A. 84:7763-7767(1987).
RN   [3]
RP   SEQUENCE REVISION.
RA   Hartley M.;
RL   Submitted (NOV-1998) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   STRAIN=Sprague-Dawley; TISSUE=Brain;
RA   Groot-Kormelink P.J.;
RL   Submitted (MAR-2004) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   FUNCTION, SYNTHESIS OF 5-16, 3D-STRUCTURE MODELING, AND SUBUNIT.
RX   PubMed=15609996; DOI=10.1021/bi048918g;
RA   Ellison M., Gao F., Wang H.L., Sine S.M., McIntosh J.M., Olivera B.M.;
RT   "Alpha-conotoxins ImI and ImII target distinct regions of the human alpha7
RT   nicotinic acetylcholine receptor and distinguish human nicotinic receptor
RT   subtypes.";
RL   Biochemistry 43:16019-16026(2004).
RN   [6]
RP   SUBUNIT, AND MUTAGENESIS OF LEU-118; VAL-135 AND PHE-143.
RX   PubMed=15929983; DOI=10.1074/jbc.m504229200;
RA   Dutertre S., Nicke A., Lewis R.J.;
RT   "Beta2 subunit contribution to 4/7 alpha-conotoxin binding to the nicotinic
RT   acetylcholine receptor.";
RL   J. Biol. Chem. 280:30460-30468(2005).
RN   [7]
RP   SUBUNIT, MUTAGENESIS OF THR-83; VAL-135 AND PHE-143, AND SITES THR-83;
RP   VAL-135 AND PHE-143.
RX   PubMed=16964981; DOI=10.1021/bi0611715;
RA   Shiembob D.L., Roberts R.L., Luetje C.W., McIntosh J.M.;
RT   "Determinants of alpha-conotoxin BuIA selectivity on the nicotinic
RT   acetylcholine receptor beta subunit.";
RL   Biochemistry 45:11200-11207(2006).
CC   -!- FUNCTION: After binding acetylcholine, the AChR responds by an
CC       extensive change in conformation that affects all subunits and leads to
CC       opening of an ion-conducting channel across the plasma membrane
CC       permeable to sodiun ions.
CC   -!- SUBUNIT: Neuronal AChR is composed of two different types of subunits:
CC       alpha and beta. Beta-2 subunit can be combined to alpha-2, alpha-3 or
CC       alpha-4 to give rise to functional receptors, complexes with beta-2 may
CC       be heteropentamers. Alpha-2/4:beta-2 nAChR complexes are proposed to
CC       exist in two subtypes: LS (low agonist sensitivity) with a (alpha-
CC       2/4)3:(beta-2)2 and HS (high agonist sensitivity) with a (alpha-
CC       2/4)2:(beta-2)3 stoichiometry; the subtypes differ in their subunit
CC       binding interfaces which are involved in ligand binding. Interacts with
CC       RIC3; which is required for proper folding and assembly. Interacts with
CC       LYPD6. The heteropentamer alpha3-beta-2 interacts with alpha-conotoxins
CC       BuIA, MII, ImI, ImII, PnIA and GID (PubMed:15609996, PubMed:15929983,
CC       PubMed:16964981). The heteropentamer alpha-4-beta-2 interacts with the
CC       alpha-conotoxins PnIA, GID and MII (PubMed:15929983). {ECO:0000250,
CC       ECO:0000250|UniProtKB:P17787, ECO:0000269|PubMed:15609996,
CC       ECO:0000269|PubMed:15929983, ECO:0000269|PubMed:16964981}.
CC   -!- INTERACTION:
CC       P12390; P09483: Chrna4; NbExp=6; IntAct=EBI-9008812, EBI-7842410;
CC   -!- SUBCELLULAR LOCATION: Postsynaptic cell membrane; Multi-pass membrane
CC       protein. Cell membrane; Multi-pass membrane protein.
CC   -!- TISSUE SPECIFICITY: Expressed in most regions of the CNS.
CC   -!- SIMILARITY: Belongs to the ligand-gated ion channel (TC 1.A.9) family.
CC       Acetylcholine receptor (TC 1.A.9.1) subfamily. Beta-2/CHRNB2 sub-
CC       subfamily. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; L31622; AAC78724.1; -; mRNA.
DR   EMBL; AY574258; AAS90354.1; -; mRNA.
DR   PIR; JH0174; JH0174.
DR   RefSeq; NP_062170.1; NM_019297.1.
DR   AlphaFoldDB; P12390; -.
DR   SMR; P12390; -.
DR   ComplexPortal; CPX-170; Neuronal nicotinic acetylcholine receptor complex, 2xalpha4-3xbeta2.
DR   ComplexPortal; CPX-171; Neuronal nicotinic acetylcholine receptor complex, 3xalpha4-2xbeta2.
DR   ComplexPortal; CPX-178; Neuronal nicotinic acetylcholine receptor complex, alpha2-beta2.
DR   ComplexPortal; CPX-190; Neuronal nicotinic acetylcholine receptor complex, alpha3-alpha5-beta2.
DR   ComplexPortal; CPX-191; Neuronal nicotinic acetylcholine receptor complex, alpha3-beta2.
DR   ComplexPortal; CPX-203; Neuronal nicotinic acetylcholine receptor complex, alpha3-alpha6-beta2-beta3.
DR   ComplexPortal; CPX-215; Neuronal nicotinic acetylcholine receptor complex, alpha4-alpha5-beta2.
DR   ComplexPortal; CPX-237; Neuronal nicotinic acetylcholine receptor complex, alpha7-beta2.
DR   CORUM; P12390; -.
DR   IntAct; P12390; 6.
DR   STRING; 10116.ENSRNOP00000028200; -.
DR   BindingDB; P12390; -.
DR   ChEMBL; CHEMBL1907587; -.
DR   ChEMBL; CHEMBL1907592; -.
DR   ChEMBL; CHEMBL1907596; -.
DR   ChEMBL; CHEMBL3137275; -.
DR   DrugCentral; P12390; -.
DR   GlyCosmos; P12390; 2 sites, No reported glycans.
DR   GlyGen; P12390; 2 sites.
DR   PhosphoSitePlus; P12390; -.
DR   SwissPalm; P12390; -.
DR   PaxDb; 10116-ENSRNOP00000028200; -.
DR   Ensembl; ENSRNOT00000028200.4; ENSRNOP00000028200.2; ENSRNOG00000020778.4.
DR   Ensembl; ENSRNOT00055036806; ENSRNOP00055029894; ENSRNOG00055021542.
DR   Ensembl; ENSRNOT00060045994; ENSRNOP00060038185; ENSRNOG00060026560.
DR   Ensembl; ENSRNOT00065047496; ENSRNOP00065038972; ENSRNOG00065027552.
DR   GeneID; 54239; -.
DR   KEGG; rno:54239; -.
DR   UCSC; RGD:2350; rat.
DR   AGR; RGD:2350; -.
DR   CTD; 1141; -.
DR   RGD; 2350; Chrnb2.
DR   eggNOG; KOG3645; Eukaryota.
DR   GeneTree; ENSGT00940000158417; -.
DR   HOGENOM; CLU_018074_1_3_1; -.
DR   InParanoid; P12390; -.
DR   OMA; MAWRSGP; -.
DR   OrthoDB; 5489962at2759; -.
DR   PhylomeDB; P12390; -.
DR   TreeFam; TF315605; -.
DR   Reactome; R-RNO-629587; Highly sodium permeable postsynaptic acetylcholine nicotinic receptors.
DR   Reactome; R-RNO-629594; Highly calcium permeable postsynaptic nicotinic acetylcholine receptors.
DR   Reactome; R-RNO-629597; Highly calcium permeable nicotinic acetylcholine receptors.
DR   PRO; PR:P12390; -.
DR   Proteomes; UP000002494; Chromosome 2.
DR   Bgee; ENSRNOG00000020778; Expressed in frontal cortex and 7 other cell types or tissues.
DR   GO; GO:0005892; C:acetylcholine-gated channel complex; IDA:RGD.
DR   GO; GO:0098981; C:cholinergic synapse; IDA:SynGO.
DR   GO; GO:0098691; C:dopaminergic synapse; ISO:RGD.
DR   GO; GO:0009897; C:external side of plasma membrane; ISO:RGD.
DR   GO; GO:0043005; C:neuron projection; IBA:GO_Central.
DR   GO; GO:0005886; C:plasma membrane; IDA:MGI.
DR   GO; GO:0044853; C:plasma membrane raft; IGI:ARUK-UCL.
DR   GO; GO:0099634; C:postsynaptic specialization membrane; IDA:SynGO.
DR   GO; GO:0098793; C:presynapse; ISO:RGD.
DR   GO; GO:0042734; C:presynaptic membrane; IDA:SynGO.
DR   GO; GO:0032991; C:protein-containing complex; IDA:RGD.
DR   GO; GO:0045202; C:synapse; IBA:GO_Central.
DR   GO; GO:0042166; F:acetylcholine binding; IDA:RGD.
DR   GO; GO:0015464; F:acetylcholine receptor activity; ISO:RGD.
DR   GO; GO:0022848; F:acetylcholine-gated monoatomic cation-selective channel activity; IDA:RGD.
DR   GO; GO:1901363; F:heterocyclic compound binding; IDA:RGD.
DR   GO; GO:0044877; F:protein-containing complex binding; IDA:RGD.
DR   GO; GO:0050997; F:quaternary ammonium group binding; IDA:RGD.
DR   GO; GO:1904315; F:transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potential; IDA:SynGO.
DR   GO; GO:0095500; P:acetylcholine receptor signaling pathway; IGI:ARUK-UCL.
DR   GO; GO:0001508; P:action potential; ISO:RGD.
DR   GO; GO:0008306; P:associative learning; ISO:RGD.
DR   GO; GO:0042113; P:B cell activation; ISO:RGD.
DR   GO; GO:0042100; P:B cell proliferation; ISO:RGD.
DR   GO; GO:0035095; P:behavioral response to nicotine; ISO:RGD.
DR   GO; GO:0006816; P:calcium ion transport; ISO:RGD.
DR   GO; GO:0021955; P:central nervous system neuron axonogenesis; ISO:RGD.
DR   GO; GO:0021952; P:central nervous system projection neuron axonogenesis; ISO:RGD.
DR   GO; GO:0050890; P:cognition; ISO:RGD.
DR   GO; GO:0001661; P:conditioned taste aversion; ISO:RGD.
DR   GO; GO:0014046; P:dopamine secretion; ISO:RGD.
DR   GO; GO:0051649; P:establishment of localization in cell; ISO:RGD.
DR   GO; GO:0021771; P:lateral geniculate nucleus development; ISO:RGD.
DR   GO; GO:0007612; P:learning; ISO:RGD.
DR   GO; GO:0007626; P:locomotory behavior; ISO:RGD.
DR   GO; GO:0051899; P:membrane depolarization; ISO:RGD.
DR   GO; GO:0007613; P:memory; ISO:RGD.
DR   GO; GO:1904456; P:negative regulation of neuronal action potential; ISO:RGD.
DR   GO; GO:0050877; P:nervous system process; ISO:RGD.
DR   GO; GO:0019228; P:neuronal action potential; ISO:RGD.
DR   GO; GO:0021631; P:optic nerve morphogenesis; ISO:RGD.
DR   GO; GO:0030890; P:positive regulation of B cell proliferation; ISO:RGD.
DR   GO; GO:0033603; P:positive regulation of dopamine secretion; ISO:RGD.
DR   GO; GO:0032226; P:positive regulation of synaptic transmission, dopaminergic; ISO:RGD.
DR   GO; GO:0099171; P:presynaptic modulation of chemical synaptic transmission; ISO:RGD.
DR   GO; GO:0045188; P:regulation of circadian sleep/wake cycle, non-REM sleep; ISO:RGD.
DR   GO; GO:0042320; P:regulation of circadian sleep/wake cycle, REM sleep; ISO:RGD.
DR   GO; GO:0048814; P:regulation of dendrite morphogenesis; ISO:RGD.
DR   GO; GO:0042053; P:regulation of dopamine metabolic process; ISO:RGD.
DR   GO; GO:0014059; P:regulation of dopamine secretion; ISO:RGD.
DR   GO; GO:0042391; P:regulation of membrane potential; ISO:RGD.
DR   GO; GO:0051963; P:regulation of synapse assembly; ISO:RGD.
DR   GO; GO:0032225; P:regulation of synaptic transmission, dopaminergic; ISO:RGD.
DR   GO; GO:1905144; P:response to acetylcholine; IDA:RGD.
DR   GO; GO:0042220; P:response to cocaine; ISO:RGD.
DR   GO; GO:0045471; P:response to ethanol; ISO:RGD.
DR   GO; GO:0001666; P:response to hypoxia; ISO:RGD.
DR   GO; GO:0035094; P:response to nicotine; IMP:RGD.
DR   GO; GO:0019233; P:sensory perception of pain; ISO:RGD.
DR   GO; GO:0007605; P:sensory perception of sound; ISO:RGD.
DR   GO; GO:0007165; P:signal transduction; ISO:RGD.
DR   GO; GO:0006939; P:smooth muscle contraction; ISO:RGD.
DR   GO; GO:0035176; P:social behavior; ISO:RGD.
DR   GO; GO:0060084; P:synaptic transmission involved in micturition; ISO:RGD.
DR   GO; GO:0007271; P:synaptic transmission, cholinergic; IMP:RGD.
DR   GO; GO:0021562; P:vestibulocochlear nerve development; ISO:RGD.
DR   GO; GO:0008542; P:visual learning; ISO:RGD.
DR   GO; GO:0007601; P:visual perception; ISO:RGD.
DR   CDD; cd19025; LGIC_ECD_nAChR_B2; 1.
DR   CDD; cd19064; LGIC_TM_nAChR; 1.
DR   Gene3D; 2.70.170.10; Neurotransmitter-gated ion-channel ligand-binding domain; 1.
DR   Gene3D; 1.20.58.390; Neurotransmitter-gated ion-channel transmembrane domain; 2.
DR   InterPro; IPR006202; Neur_chan_lig-bd.
DR   InterPro; IPR036734; Neur_chan_lig-bd_sf.
DR   InterPro; IPR006201; Neur_channel.
DR   InterPro; IPR036719; Neuro-gated_channel_TM_sf.
DR   InterPro; IPR038050; Neuro_actylchol_rec.
DR   InterPro; IPR006029; Neurotrans-gated_channel_TM.
DR   InterPro; IPR018000; Neurotransmitter_ion_chnl_CS.
DR   InterPro; IPR002394; Nicotinic_acetylcholine_rcpt.
DR   NCBIfam; TIGR00860; LIC; 1.
DR   PANTHER; PTHR18945:SF901; NEURONAL ACETYLCHOLINE RECEPTOR SUBUNIT BETA-2; 1.
DR   PANTHER; PTHR18945; NEUROTRANSMITTER GATED ION CHANNEL; 1.
DR   Pfam; PF02931; Neur_chan_LBD; 1.
DR   Pfam; PF02932; Neur_chan_memb; 1.
DR   PRINTS; PR00254; NICOTINICR.
DR   PRINTS; PR00252; NRIONCHANNEL.
DR   SUPFAM; SSF90112; Neurotransmitter-gated ion-channel transmembrane pore; 1.
DR   SUPFAM; SSF63712; Nicotinic receptor ligand binding domain-like; 1.
DR   PROSITE; PS00236; NEUROTR_ION_CHANNEL; 1.
PE   1: Evidence at protein level;
KW   Cell membrane; Disulfide bond; Glycoprotein; Ion channel; Ion transport;
KW   Ligand-gated ion channel; Membrane; Postsynaptic cell membrane; Receptor;
KW   Reference proteome; Signal; Synapse; Transmembrane; Transmembrane helix;
KW   Transport.
FT   SIGNAL          1..24
FT                   /evidence="ECO:0000255"
FT   CHAIN           25..500
FT                   /note="Neuronal acetylcholine receptor subunit beta-2"
FT                   /id="PRO_0000000381"
FT   TOPO_DOM        25..237
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        238..258
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        259..266
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        267..287
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        288..299
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        300..320
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        321..458
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        459..479
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   SITE            83
FT                   /note="Key residue that may interfere with effective access
FT                   of the conotoxin BuIA to the channel binding site"
FT                   /evidence="ECO:0000305|PubMed:16964981"
FT   SITE            118
FT                   /note="Key residue that may play an important stabilizing
FT                   role for the interaction with alpha-conotoxins PnIA, GID
FT                   and MII, allowing them to bind deep into the nAChR cleft"
FT                   /evidence="ECO:0000305|PubMed:15929983"
FT   SITE            135
FT                   /note="Key residue for a rapid dissociation (K(off)) from
FT                   the conotoxin BuIA"
FT                   /evidence="ECO:0000305|PubMed:16964981"
FT   SITE            143
FT                   /note="Key residue for a rapid dissociation (K(off)) from
FT                   the conotoxin BuIA"
FT                   /evidence="ECO:0000305|PubMed:16964981"
FT   CARBOHYD        50
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        167
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        154..168
FT                   /evidence="ECO:0000250"
FT   MUTAGEN         83
FT                   /note="T->D: 9-fold increase in affinity to the conotoxin
FT                   BuIA (15-fold decrease in K(off))."
FT                   /evidence="ECO:0000269|PubMed:16964981"
FT   MUTAGEN         83
FT                   /note="T->G: 12-fold increase in affinity to the conotoxin
FT                   BuIA (11-fold decrease in K(off))."
FT                   /evidence="ECO:0000269|PubMed:16964981"
FT   MUTAGEN         83
FT                   /note="T->K: 20-fold increase in affinity to the conotoxin
FT                   BuIA (37-fold decrease in K(off)); 2-fold decrease in
FT                   affinity to the conotoxin MII (no change in K(off), but 2-
FT                   fold decrease in K(on))."
FT                   /evidence="ECO:0000269|PubMed:16964981"
FT   MUTAGEN         83
FT                   /note="T->S: 19-fold increase in affinity to the conotoxin
FT                   BuIA (7-fold decrease in K(off))."
FT                   /evidence="ECO:0000269|PubMed:16964981"
FT   MUTAGEN         83
FT                   /note="T->V: 3-fold increase in affinity to the conotoxin
FT                   BuIA (2-fold decrease in K(off))."
FT                   /evidence="ECO:0000269|PubMed:16964981"
FT   MUTAGEN         118
FT                   /note="L->Q: 40-fold, 165-fold, and 300-fold decrease in
FT                   inhibition of alpha-3-beta-2(L118Q) nAChR by alpha-
FT                   conotoxins PnIA, GID and MII, respectively."
FT                   /evidence="ECO:0000269|PubMed:15929983"
FT   MUTAGEN         135
FT                   /note="V->A: Very small decrease or no change in inhibition
FT                   of alpha-3-beta-2(V135A) nAChR by alpha-conotoxins PnIA,
FT                   GID and MII."
FT                   /evidence="ECO:0000269|PubMed:15929983"
FT   MUTAGEN         135
FT                   /note="V->G: No change in inhibition of alpha-3-beta-
FT                   2(V135G) nAChR by alpha-conotoxins GID and MII. 4.4-fold
FT                   decrease in inhibition of alpha-3-beta-2(V135G) nAChR by
FT                   alpha-conotoxins PnIA."
FT                   /evidence="ECO:0000269|PubMed:15929983"
FT   MUTAGEN         135
FT                   /note="V->I: 8.3-fold decrease in affinity to the conotoxin
FT                   BuIA (4-fold increase in K(off) and a 2-fold decrease in
FT                   K(on))."
FT                   /evidence="ECO:0000269|PubMed:16964981"
FT   MUTAGEN         143
FT                   /note="F->A: No change in inhibition of alpha-3-beta-
FT                   2(F143A) nAChR by alpha-conotoxins PnIA, GID and MII. 12-
FT                   fold and 6.6-fold increase in inhibition of alpha-4-beta-
FT                   2(F143A) nAChR by alpha-conotoxins GID and MII,
FT                   respectively, but no change in inhibition of the same
FT                   receptor by alpha-conotoxin PnIA."
FT                   /evidence="ECO:0000269|PubMed:15929983"
FT   MUTAGEN         143
FT                   /note="F->Q: 6.6-fold increase in affinity to the conotoxin
FT                   BuIA (7-fold decrease in K(off))."
FT                   /evidence="ECO:0000269|PubMed:16964981"
SQ   SEQUENCE   500 AA;  56909 MW;  54C007A48225931C CRC64;
     MAGHSNSMAL FSFSLLWLCS GVLGTDTEER LVEHLLDPSR YNKLIRPATN GSELVTVQLM
     VSLAQLISVH EREQIMTTNV WLTQEWEDYR LTWKPEDFDN MKKVRLPSKH IWLPDVVLYN
     NADGMYEVSF YSNAVVSYDG SIFWLPPAIY KSACKIEVKH FPFDQQNCTM KFRSWTYDRT
     EIDLVLKSDV ASLDDFTPSG EWDIIALPGR RNENPDDSTY VDITYDFIIR RKPLFYTINL
     IIPCVLITSL AILVFYLPSD CGEKMTLCIS VLLALTVFLL LISKIVPPTS LDVPLVGKYL
     MFTMVLVTFS IVTSVCVLNV HHRSPTTHTM APWVKVVFLE KLPTLLFLQQ PRHRCARQRL
     RLRRRQRERE GAGALFFREG PAADPCTCFV NPASVQGLAG AFRAEPTAAG PGRSVGPCSC
     GLREAVDGVR FIADHMRSED DDQSVREDWK YVAMVIDRLF LWIFVFVCVF GTVGMFLQPL
     FQNYTATTFL HPDHSAPSSK
//
